KARMALI, PRIYA,SRIDHAR, C. NAGARAJAN,NIITSU, YOSHIRO,HOU, ZHENG,GAUDETTE, JOHN A.,KNOPOV, VICTOR,AHMADIAN, MOHAMMAD,TANAKA, YASUNOBU,AKOPIAN, VIOLETTA,PAYNE, JOSEPH E.,WITTE, RICHARD P.,PERELMAN, LORE
申请号：
CA2837101
公开号：
CA2837101A1
申请日:
2012.06.08
申请国别(地区):
CA
年份:
2012
代理人:
摘要：
Here described are compounds of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group； wherein R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol； wherein X is selected from a group consisting of -CH2-, -S-, and -O- or absent； wherein Y is selected from -(CH2)n, -S(CH2)n, -O(CH2)n-, thiophene, -SO2(CH2)n-, and ester, wherein n = 1 -4； wherein a = 1 -4； wherein b=l -4； wherein c=l-4； and wherein Z is a counterion； and compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell； wherein m and n are independently 0, 1, 2 or 3； and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including one or both of these compounds which are useful for the delivery of therapeutic agents； and methods of using these compositions and pharmaceutical formulations.
